Quantcast

Latest severe chronic pain Stories

2014-03-14 08:26:42

BUNAVAIL PDUFA date June 7, 2014; Plans underway for potential Q3 2014 launch RALEIGH, N.C., March 14, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's 2013 financials and achievements as well as an update on business operations and upcoming milestones for...

2011-04-05 06:00:00

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain. (Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) "The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA...

2011-01-20 10:40:00

STAMFORD, Conn., Jan. 20, 2011 /PRNewswire/ -- Butrans(TM) (buprenorphine) Transdermal System CIII from Purdue Pharma L.P. is now available by prescription and indicated for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is the first opioid analgesic that delivers continuous release of buprenorphine for seven days. To view the multimedia assets associated...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.